CU24525B1 - Derivado de quinoleína para tratar y prevenir infecciones virales - Google Patents

Derivado de quinoleína para tratar y prevenir infecciones virales

Info

Publication number
CU24525B1
CU24525B1 CU2017000109A CU20170109A CU24525B1 CU 24525 B1 CU24525 B1 CU 24525B1 CU 2017000109 A CU2017000109 A CU 2017000109A CU 20170109 A CU20170109 A CU 20170109A CU 24525 B1 CU24525 B1 CU 24525B1
Authority
CU
Cuba
Prior art keywords
derivative
quinolein
treat
viral infections
prevent viral
Prior art date
Application number
CU2017000109A
Other languages
English (en)
Other versions
CU20170109A7 (es
Inventor
Noëlie Campos
Pauline Fornarelli
Aude Garcel
Florence Mahuteau
Romain Najman
Didier Scherrer
Jamal Tazi
Audrey Vautrin
Original Assignee
Abivax
Centre Nat Rech Scient
Inst Curie
Univ Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abivax, Centre Nat Rech Scient, Inst Curie, Univ Montpellier filed Critical Abivax
Publication of CU20170109A7 publication Critical patent/CU20170109A7/es
Publication of CU24525B1 publication Critical patent/CU24525B1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

<p>La presente invención se refiere derivados de quinoleínas de la fórmula (1) y (4)</p> <p>ESPACIO PARA FÓRMULAS</p> <p>o una de sus sales farmacéuticamente aceptables. La presente invención se refiere además al derivado de quinoleína para el medicamento y para su uso en el tratamiento o prevención de una infección viral o retroviral y en particular el SIDA o una afección relacionada con el SIDA o el virus de inmunodeficiencia humana (VIH).</p>
CU2017000109A 2015-02-23 2016-02-19 Derivado de quinoleína para tratar y prevenir infecciones virales CU24525B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15305274.1A EP3059236A1 (en) 2015-02-23 2015-02-23 A new quinoline derivative for use in the treatment and prevention of viral infections
PCT/EP2016/053532 WO2016135052A1 (en) 2015-02-23 2016-02-19 A new quinoline derivative for use in the treatment and prevention of viral infections

Publications (2)

Publication Number Publication Date
CU20170109A7 CU20170109A7 (es) 2018-02-08
CU24525B1 true CU24525B1 (es) 2021-06-08

Family

ID=52629497

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2017000109A CU24525B1 (es) 2015-02-23 2016-02-19 Derivado de quinoleína para tratar y prevenir infecciones virales

Country Status (22)

Country Link
US (1) US10329317B2 (es)
EP (2) EP3059236A1 (es)
JP (1) JP6797126B2 (es)
KR (1) KR102583506B1 (es)
CN (1) CN107531681B (es)
AU (1) AU2016223687B2 (es)
BR (1) BR112017017500B1 (es)
CA (1) CA2975577C (es)
CU (1) CU24525B1 (es)
DK (1) DK3262037T3 (es)
ES (1) ES2785374T3 (es)
HR (1) HRP20200649T1 (es)
HU (1) HUE048577T2 (es)
LT (1) LT3262037T (es)
MX (1) MX2017010506A (es)
PL (1) PL3262037T3 (es)
PT (1) PT3262037T (es)
RS (1) RS60369B1 (es)
RU (1) RU2723013C2 (es)
SI (1) SI3262037T1 (es)
WO (1) WO2016135052A1 (es)
ZA (1) ZA201705633B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
EP3059591A1 (en) 2015-02-23 2016-08-24 Abivax Methods for screening compounds for treating or preventing a viral infection or a virus-related condition
US20190034990A1 (en) * 2017-07-26 2019-01-31 International Business Machines Corporation Information insight system for providers of products or services
EP3669874A1 (en) * 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use in the treatment or prevention of cancer
WO2021186053A1 (en) * 2020-03-20 2021-09-23 Abivax Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
EP3881844A1 (en) * 2020-03-20 2021-09-22 Abivax Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
EP3884946A1 (en) * 2020-03-25 2021-09-29 Abivax Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
WO2022247920A1 (zh) * 2021-05-27 2022-12-01 江苏恒瑞医药股份有限公司 喹啉胺类化合物、其制备方法及其在医药上的应用
EP4201948A1 (en) 2021-12-21 2023-06-28 Abivax Method of preparation of 1-(n-(quinolin-2-yl)-(phenylamino)-1-deoxy-beta-d-glucopyranuronic acid derivatives
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
EP4215196A1 (en) * 2022-01-24 2023-07-26 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor
CN116617226A (zh) * 2023-06-21 2023-08-22 湖北工业大学 新型吲哚喹啉衍生物作为肠道病毒71型抑制剂的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2436786A1 (fr) 1978-09-21 1980-04-18 Anvar Nouveaux derives des pyrido (4,3-b) carbazoles (ellipticines), substitues en position 1 par une chaine polyaminee, leur obtention et leur application a titre de medicaments
FR2627493B1 (fr) 1988-02-23 1991-10-31 Sanofi Sa Procede de preparation de derives d'isoquinoleine
FR2645861A1 (fr) 1989-04-17 1990-10-19 Inst Nat Sante Rech Med Utilisation de dipyrido (4,3-b) (3,4-f) indoles pour la preparation de medicaments utiles pour le traitement du sida
US5354853A (en) * 1993-03-12 1994-10-11 Genzyme Corporation Phospholipid-saccharide conjugates
FR2859474B1 (fr) 2003-09-04 2006-01-13 Centre Nat Rech Scient Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage
CN106928194B (zh) * 2009-06-12 2019-11-12 Abivax公司 用于治疗过早衰老和尤其是早衰的化合物
EP2465502A1 (en) 2010-12-15 2012-06-20 Société Splicos Compounds useful for treating AIDS
RU2681943C9 (ru) * 2013-07-05 2019-05-16 Абивакс Соединения, полезные для лечения заболеваний, вызванных ретровирусами
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
EP2975034A1 (en) 2014-07-17 2016-01-20 Abivax A quinoline derivative for the treatment of inflammatory diseases and AIDS

Also Published As

Publication number Publication date
ES2785374T3 (es) 2020-10-06
KR20170129698A (ko) 2017-11-27
BR112017017500B1 (pt) 2023-04-04
EP3262037A1 (en) 2018-01-03
JP6797126B2 (ja) 2020-12-09
JP2018507215A (ja) 2018-03-15
WO2016135052A1 (en) 2016-09-01
RS60369B1 (sr) 2020-07-31
US20180030078A1 (en) 2018-02-01
CA2975577C (en) 2020-04-07
SI3262037T1 (sl) 2020-09-30
RU2017128643A3 (es) 2019-04-15
BR112017017500A2 (pt) 2018-04-17
RU2723013C2 (ru) 2020-06-08
US10329317B2 (en) 2019-06-25
PT3262037T (pt) 2020-04-09
CA2975577A1 (en) 2016-09-01
EP3262037B1 (en) 2020-02-12
RU2017128643A (ru) 2019-03-25
PL3262037T3 (pl) 2020-10-19
HUE048577T2 (hu) 2020-07-28
AU2016223687B2 (en) 2020-03-19
LT3262037T (lt) 2020-07-10
DK3262037T3 (da) 2020-05-04
CN107531681B (zh) 2020-11-24
ZA201705633B (en) 2018-12-19
AU2016223687A1 (en) 2017-08-31
MX2017010506A (es) 2017-11-13
CN107531681A (zh) 2018-01-02
EP3059236A1 (en) 2016-08-24
HRP20200649T1 (hr) 2020-10-16
CU20170109A7 (es) 2018-02-08
KR102583506B1 (ko) 2023-09-26

Similar Documents

Publication Publication Date Title
CU24525B1 (es) Derivado de quinoleína para tratar y prevenir infecciones virales
UY37710A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
UY36649A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
UY36648A (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
TR201909152T4 (tr) Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımı.
DOP2016000265A (es) Inhibidores de la transcriptasa inversa de nucleósidos sustituidos en 4’
CU20150096A7 (es) Compuestos de amida y composición farmacéutica para el tratamiento de vih
GT201700234A (es) Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue
CY1122792T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου
EA201791872A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
UY35263A (es) Compuestos terapéuticos
DOP2018000035A (es) Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana
UY37645A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CR20150313A (es) Composiciones farmacéuticas
UY37646A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
EP3757105A3 (en) Polycyclic pyridone derivative having integrase inhibitory activity
CL2017000714A1 (es) Composiciones farmacéuticas de acción prolongada
DOP2021000062A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana.
BR112018002689A2 (pt) composto, composição útil e método para tratamento de infecção por hiv
BR112017028456A2 (pt) composto, e, método de prevenção e/ou tratamento de hiv
UY37555A (es) Derivados de ácido piridin-3-il-acético como inhibidores de la replicación del virus de la inmunodeficiencia humana
BR112018003181A2 (pt) composto, composição, e, método para tratar infecção por hiv
BR112018002678A2 (pt) composto, composição, e, método para tratar infecção por hiv
BR112018000253A2 (pt) composto, composição, e, método para tratar a infecção pelo hiv.
BR112018002681A2 (pt) ?composto, composição, e, método para tratamento de infecção por hiv?